The accepted standard adjuvant therapy for managing and treating CM (stage III or IV) is using an inhibitor of the programmed cell death protein − 1 (PD-1) (Patrinely et al. 2021; Carlino et al. 2021). The gene discussed is PDCD1; the disease is cutaneous mastocytosis.